Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22074784 | 0.83 | MAP3K12 (0.35) | MAP3K12ROCK1CDC42BPB | |
| SCHEMBL21658975 | 0.77 | MAP3K12 (0.41) | MAP3K12 | |
| SCHEMBL22074785 | 0.69 | ROCK1 (0.49) | ROCK1CDC42BPBMAPK9MAPK10MAPK11 | |
| SCHEMBL21658974 | 0.60 | MAP3K12 (0.40) | MAP3K12 | |
| SCHEMBL22074957 | 0.58 | MAP3K12 (0.41) | MAP3K12 | |
| SCHEMBL13910999 | 0.57 | HSP90AA1 (0.50) | MAPK9MAPK10MAPK11MAPK14 | |
| SCHEMBL673108 | 0.57 | ROCK1 (0.36) | ROCK1CDC42BPB | |
| SCHEMBL10402322 | 0.56 | HSP90AA1 (0.48) | ROCK1CDC42BPBMAPK9MAPK10MAPK11 | |
| SCHEMBL2814353 | 0.55 | HSP90AA1 (0.52) | MAPK9MAPK10MAPK11MAPK14 | |
| SCHEMBL30595872 | 0.55 | HSP90AA1 (0.52) | MAPK9MAPK10MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | BCHE, SNCA, HAX1 | MAP3K12 1980/4885ROCK1 778/4885CDC42BPB 2151/4885 |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | MAP3K12 1980/4885ROCK1 778/4885CDC42BPB 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.